Trader: Time To Get...
Health Care: Drugs
Immunomedics Inc. (IMMU: NASDAQ)
$3.28 -0.06 | -1.80%
05/24/12 - 12:43 PM ET
37.62K / 274.60K
Vol / Avg. Vol:3.33 / 3.34
Open / Prev. Close:3.26 - 3.34
Today's Range:2.85 - 4.47
52 Wk Range:0.30%
Performance YTD:TheStreet Rating:
Portfolios with IMMU
- Portfolio NameUser Type
- Contributor5 Stocks to Watch Under $5
- Usertoms
- UserASCO 2010
- UserPortfolioRadical1
- UserPART 7 JPMorgan 28th Annual...
- Userinvestone
- Usermchish Portfolio 1
- UserASCO 2009 Nymph's Watch List.
- UserPART 6 JPMorgan 27th Annual...
- ContributorBarron's Insider Purchases ...
Latest IMMU Headlines from TheStreet
- Immunomedics Inc. Stock Downgraded (IMMU) 05.10.12 | 04:05 am
- Immunomedics Inc. Stock Upgraded (IMMU) 02.10.12 | 06:02 am
- 5 Stocks to Watch Under $5 12.29.11 | 10:12 am
- Immunomedics Inc. Stock Downgraded (IMMU) 11.14.11 | 05:11 am
- Immunomedics Inc. Stock Upgraded (IMMU) 08.26.11 | 07:08 am
- Immunomedics Inc. Stock Downgraded (IMMU) 06.02.11 | 07:06 am
- Immunomedics To Report On New Antibody-SN-38 Conjugates And Diverse Novel DNL Agents At AACR 102nd Annual Meeting 03.28.11 | 08:03 am
- Immunomedics Awarded Three US Patents Covering Its Cancer Therapeutic Product Candidates And Technologies 03.24.11 | 08:03 am
- Immunomedics Awarded Two Additional U.S. Patents For Dock-and-Lock Technology 03.09.11 | 08:03 am
- Immunomedics Announces Presentations At Upcoming Healthcare Conferences 02.25.11 | 08:02 am
Press Releases for IMMU
Partner Headlines for IMMU
- CNS Cure Priority for UCB & Partner - Analyst Blog - Zacks 01.13.12 | 10:01 am
- Immunomedics Reports Subcutaneous Injections of Low-Dose Veltuzumab Produced High Rates of Response in Relapsed Immune - Benzinga 12.12.11 | 01:12 pm
- Baker's Dozen Trying To Beat The Odds In Pancreatic Cancer - Seeking Alpha 10.25.11 | 08:10 am
- Immunomedics Reports Advances With New Imaging Agent Developments for Positron Emission Tomography - Benzinga 06.08.11 | 04:06 pm
- UCB's Progress On-Track - Analyst Blog - Zacks 01.12.11 | 09:01 am
- Monoclonal Antibody Companies Command Premiums - Seeking Alpha 07.12.10 | 08:07 am
- Zacks Analyst Blog Highlights: Immunomedics, Human Genome, GlaxoSmithKline, CNOOC and Devon Energy - Press Releases - Zacks 06.22.10 | 09:06 am
- UPDATE 1-Immunomedics says lupus drug shows efficacy - Reuters 06.16.10 | 07:06 am
- Weekly Street Sentiment: Investigations Drive Market - Seeking Alpha 05.17.10 | 03:05 am
